Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy

BACKGROUND: TP53 mutations are frequent in breast cancer, however their clinical relevance in terms of response to chemotherapy is controversial. METHODS: 450 pre-therapeutic, formalin-fixed, paraffin-embedded core biopsies from the phase II neoadjuvant GeparSixto trial that included HER2-positive a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Darb-Esfahani, Silvia, Denkert, Carsten, Stenzinger, Albrecht, Salat, Christoph, Sinn, Bruno, Schem, Christian, Endris, Volker, Klare, Peter, Schmitt, Wolfgang, Blohmer, Jens-Uwe, Weichert, Wilko, Möbs, Markus, Tesch, Hans, Kümmel, Sherko, Sinn, Peter, Jackisch, Christian, Dietel, Manfred, Reimer, Toralf, Loi, Sherene, Untch, Michael, von Minckwitz, Gunter, Nekljudova, Valentina, Loibl, Sibylle
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Priority Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356512/
https://ncbi.nlm.nih.gov/pubmed/27611952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11891
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados